Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease
news
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class anti-KLRG1 antibody for the treatment of inclusion body myositis as well as continued development of additional clinical programs Newton, Massachusetts, August 17, 2023 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies
August 17, 2023
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune PipelinePress Releases
